Abstract | OBJECTIVE: METHODS: A single-center, retrospective study was conducted. At baseline, female patients with relapsing GLS (n = 46) were treated with MPA 0.1% applied once daily for 8 weeks. Visual Analog Scale (VAS) score for vulvar pruritus and Investigator's Global Assessment ( IGA) score were recorded at baseline, weeks 8 and 20. At week 8, patients responsive to treatment (n = 38) were further treated with MPA 0.1% twice weekly (n = 15), tacrolimus once daily (n = 13) or topical emollient once daily (n = 10), as maintenance therapy until week 20. RESULT: Both VAS and IGA median score was significantly decreased from baseline to week 8 (p = 0.000). At week 20, both median VAS and IGA scores differed significantly between patients treated with emollient and patients treated with MPA 0.1% (p = 0.000) and patients treated with emollient and patients treated with tacrolimus (p = 0.000); patients treated with MPA 0.1% presented no significant difference in either median VAS score (p = 0.032) or median IGA score (p = 0.636) at week 20 compared to patients treated with tacrolimus. CONCLUSIONS: MPA 0.1% is effective in relapsing female GLS. MPA 0.1% and tacrolimus have equal efficacy in preventing relapses.
|
Authors | Aikaterini Patsatsi, Aikaterini Kyriakou, Dimitrios Vavilis, Athanasios Mantas, Christos Patsialas, Dimitrios Sotiriadis |
Journal | The Journal of dermatological treatment
(J Dermatolog Treat)
Vol. 24
Issue 5
Pg. 336-9
(Oct 2013)
ISSN: 1471-1753 [Electronic] England |
PMID | 23164046
(Publication Type: Journal Article)
|
Chemical References |
- Dermatologic Agents
- Emollients
- methylprednisolone aceponate
- Tacrolimus
- Methylprednisolone
|
Topics |
- Aged
- Dermatologic Agents
(administration & dosage)
- Emollients
(administration & dosage)
- Female
- Humans
- Lichen Sclerosus et Atrophicus
(drug therapy)
- Methylprednisolone
(administration & dosage, analogs & derivatives)
- Middle Aged
- Retrospective Studies
- Secondary Prevention
- Tacrolimus
(administration & dosage)
- Treatment Outcome
|